Abstract

Alzheimer's disease (AD) is an age-related disorder characterized by progressive cognitive decline and dementia. Alzheimer's disease is an increasingly prevalent disease with 5.3 million people in the United States currently affected. This number is a 10 percent increase from previous estimates and is projected to sharply increase to 8 million by 2030; it is the sixth-leading cause of death. In the United States the direct and indirect costs of Alzheimer's and other dementias to Medicare, Medicaid and businesses amount to more than $172 billion each year. Despite intense research efforts, effective disease-modifying therapies for this devastating disease remain elusive. At present, the few agents that are FDA-approved for the treatment of AD have demonstrated only modest effects in modifying clinical symptoms for relatively short periods and none has shown a clear effect on disease progression. New therapeutic approaches are desperately needed. Although the idea that vascular defects are present in AD and may be important in disease pathogenesis was suggested over 25 years ago, little work has focused on an active role for cerebrovascular mechanisms in the pathogenesis of AD. Nevertheless, increasing literature supports a vascular-neuronal axis in AD as shared risk factors for both AD and atherosclerotic cardiovascular disease implicate vascular mechanisms in the development and/or progression of AD. Also, chronic inflammation is closely associated with cardiovascular disease, as well as a broad spectrum of neurodegenerative diseases of aging including AD. In this review we summarize data regarding, cardiovascular risk factors and vascular abnormalities, neuro- and vascular-inflammation, and brain endothelial dysfunction in AD. We conclude that the endothelial interface, a highly synthetic bioreactor that produces a large number of soluble factors, is functionally altered in AD and contributes to a noxious CNS milieu by releasing inflammatory and neurotoxic species.

Highlights

  • Alzheimer’s disease (AD) is an age-related disorder characterized by progressive cognitive decline and dementia

  • Used diagnostic criteria classify dementia as either vascular or AD-driven; despite the reality of clinical practice where vascular comorbidity may be present in 30%-60% of AD patients and, AD pathology may be present in 40%-80% of vascular dementia patients [2]

  • Increasing literature supports a vascular-neuronal axis in AD as shared risk factors for both AD and atherosclerotic cardiovascular disease implicate vascular mechanisms in the development and/or progression of AD

Read more

Summary

Introduction

Alzheimer’s disease (AD) is an age-related disorder characterized by progressive cognitive decline and dementia. Brain microvessels express and release a large number of inflammatory proteins (1L-1b, IL-6, IL-8, TNFa, TGFb, MCP-1); many of which have been implicated in angiogenesis [54,55,93] In addition, the vasculature demonstrates up-regulation of specific molecules thought to be important regulators/markers of the angiogenic process including thrombin, VEGF, angiopoietin-2, integrins (aVb3 aVb5), and hypoxia inducible factor 1a (HIF-1a) [93,108,109]. The efficacy of COX-2 selective inhibitors in AD treatment may be related to the inhibition of prostaglandins, NO and TNFa, all of which are important to both inflammation and angiogenesis [131] Thalidomide, another antiangiogenic drug which blocks endothelial cell activation and suppresses release of VEGF and TNFa, appears protective in animal models of AD preventing memory impairment induced by Ab [132,133].

Conclusions
12. Marx J
17. Iadecola C
21. Stampfer MJ
30. Kalaria RN
39. Scheibel AB
50. Claudio L
61. Ross R
66. Tarkowski E
70. Wyss-Coray T
Findings
77. Pasinetti GML
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call